Since most clinical laboratories are currently applying NGS-based gene panel sequencing to detect TP53 mutations, often including other CLL-related genes (that are usually not reported), it would be informative to extend the analysis to other genes to identify high-risk patients in routine diagnostics. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.